No Data
No Data
Tonghe Pharmaceutical (300636.SZ) reported first-quarter results, net profit of 43.5628 million yuan, an increase of 31.62% over the previous year
Tonghe Pharmaceutical (300636.SZ) released its report for the first quarter of 2024, with revenue of 206 million yuan, and...
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Stock Rockets 32% As Investors Are Less Pessimistic Than Expected
Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) shareholders would be excited to see that the share price has had a great month, posting a 32% gain and recovering from prior weakness. Not al
Pacific Securities: The API industry is in the de-inventory phase or nearing its end, and the 24-year sector is expected to usher in a beta market
The Zhitong Finance App learned that Pacific Securities released a research report saying that in December 2023, production of chemical raw materials by industrial enterprises above the Chinese scale began to resume growth, with a year-on-year increase of 2% and a month-on-month increase of 35%. From January to February 2024, production was 546,000 tons. Although the year-on-year decline was 7.6%, it has already exceeded the same period in 2021 and 2022, continuing the improvement at the end of 2023. As major product patents expire one after another and overseas inventory removal gradually comes to an end, the demand side of the API sector is expected to gradually pick up in 2024, ushering in a beta market. Recommended attention: 1) Continued direction in 2024
Jiangxi Synergy Pharmaceutical Co., Ltd.'s (SZSE:300636) Market Cap Rose CN¥403m Last Week; Retail Investors Who Hold 58% Profited and so Did Insiders
Key Insights The considerable ownership by retail investors in Jiangxi Synergy Pharmaceutical indicates that they collectively have a greater say in management and business strategy The top 25 share
Tonghe Pharmaceutical (300636.SZ): Approved as a high-tech enterprise
On February 23, Gelonghui | Tonghe Pharmaceutical (300636.SZ) announced that the company was recognized as a high-tech enterprise in 2007 and obtained the “High-tech Enterprise Certificate” issued by the relevant departments, and later passed several reviews and re-accreditation. In 2023, the company carried out the high-tech enterprise re-certification process in accordance with relevant regulations, and recently received the “High-tech Enterprise Certificate” jointly issued by the Jiangxi Provincial Department of Science and Technology, the Jiangxi Provincial Department of Finance, and the Jiangxi Provincial Taxation Bureau of the State Administration of Taxation.
Risks Still Elevated At These Prices As Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) Shares Dive 28%
To the annoyance of some shareholders, Jiangxi Synergy Pharmaceutical Co., Ltd. (SZSE:300636) shares are down a considerable 28% in the last month, which continues a horrid run for the company. The
No Data